Expect near-term selling pressure as the offering prices at only a 2% discount to market. Monitor for any further capital needs or clinical trial updates that could shift sentiment. The Phase 3 Alzheimer's readout remains the key catalyst, but the financing overhang may persist until data emerges.
ANVS drugs
ANVS drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 21 $2.15entry
- T+1 · 6mo ago +3.72%α +3.28% · $2.23
- T+5 · 6mo ago −11.63%α −13.23% · $1.90
- T+20 · 5mo ago −19.53%α −19.87% · $1.73
- T+60 · 3mo ago −19.07%α −23.37% · $1.74
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Annovis Bio is raising approximately $13.8M in net proceeds through a dilutive offering of 7.9M shares and warrants, priced at $1.90/unit (vs. last sale $1.94). The company has a going concern warning with only $14.2M cash (as of Mar 31, 2026) and an accumulated deficit of $181.3M. This capital raise, following a poor Q1 earnings report, underscores acute funding needs and dilutes existing shareholders by ~23% (excluding warrants). Traders should expect near-term price pressure given the minimal premium to market and ongoing cash burn.
Key Facts
- Offering 7,895,000 shares of common stock plus warrants to purchase up to 7,105,500 shares at $2.25 exercise price, 6-year term
- Combined offering price $1.90 per unit, net proceeds ~$13.8M
- Cash and cash equivalents of $14.2M as of March 31, 2026; company believes runway only extends to Q4 2026
- Going concern warning from independent auditor; accumulated deficit of $181.3M
- Q1 2026 earnings (filed May 15) showed increased net loss and cash burn
Financial Impact
Dilution of ~23% to existing shareholders from the common stock offering (plus additional dilution from warrants if exercised). Net proceeds of $13.8M will extend cash runway modestly but do not resolve the structural funding shortfall.
Risk Factors
- Immediate dilution and potential further offerings due to insufficient cash runway
- Clinical trial failure or delay of pivotal Phase 3 AD data
- Going concern risk if additional capital is not raised
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-064510 |
| Document: 0001104659-26-064510-index-headers.html | 0001104659-26-064510 |
| Document: 0001104659-26-064510-index.html | 0001104659-26-064510 |
| Document: 0001104659-26-064510.txt | 0001104659-26-064510 |
Track record
19 reports on ANVS
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 13, 20263d ago Press Release Neutral 5/10 Entry $0.9261 Now $0.7500 −19.02% settles Feb 11
- Nov 5, 202611d ago 8-K Bearish 7/10 Entry $0.8449 Now $0.7500 +11.23% settles Feb 4
- Nov 5, 202611d ago 424B5 Bearish 7/10 Entry $0.8449 Now $0.7500 +11.23% settles Feb 4
- Nov 5, 202611d ago Press Release Bearish 7/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
- Nov 4, 202612d ago 424B5 Bearish 6/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
- Nov 4, 202612d ago Press Release Bearish 7/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
- Nov 4, 202612d ago 8-K Bearish 7/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
- Oct 30, 202617d ago 8-K Bearish 7/10 Entry $1.08 Now $0.7500 +30.56% settles Jan 29
- Oct 19, 202628d ago 8-K Neutral 1/10 Entry $0.9783 Now $0.7500 −23.34% settles Jan 15
- Oct 15, 20264w ago SC 13G/A Neutral 3/10 Entry $1.05 Now $0.7500 −28.57% settles Jan 12
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers